Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E H Gerlach

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|April 1, 1980
Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicinR N Jones, P C Fuchs, A L Barry, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1993
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroximeJ A Washington, R N Jones, E H Gerlach, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1994
In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosaJ C McLaughlin, A L Barry, P C Fuchs, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1995
Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five yearsS A Marshall, K E Aldridge, S D Allen, et al.
Journal of Clinical Microbiology|May 1, 1992
MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacinM E Erwin, R N Jones, F P Koontz, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1986
Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolatesR N Jones, P C Fuchs, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicidA L Barry, T L Gavan, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1986
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1990
Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeaeR N Jones, P C Fuchs, J A Washington, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|April 1, 1980
Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicinR N Jones, P C Fuchs, A L Barry, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1993
Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroximeJ A Washington, R N Jones, E H Gerlach, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1994
In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosaJ C McLaughlin, A L Barry, P C Fuchs, et al.
Diagnostic Microbiology and Infectious Disease|March 1, 1995
Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five yearsS A Marshall, K E Aldridge, S D Allen, et al.
Journal of Clinical Microbiology|May 1, 1992
MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacinM E Erwin, R N Jones, F P Koontz, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1986
Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolatesR N Jones, P C Fuchs, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|May 1, 1987
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicidA L Barry, T L Gavan, R N Jones, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1986
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteriaP C Fuchs, R N Jones, A L Barry, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1990
Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeaeR N Jones, P C Fuchs, J A Washington, et al.
Pageof 9